Savient Pharma Enters Co-Promotion Deal With Ferring for Nuflexxa

Savient Pharmaceuticals, Inc. has signed a definitive agreement with Ferring Pharmaceuticals, a subsidiary of Ferring B.V., to enter a co-promotion agreement to market Nuflexxa (1 percent Sodium Hyaluronate) in the United States. Under the terms of the agreement, which is contingent upon completion of the sale of Savient's global biologics manufacturing business to Ferring B.V. and Ferring International Centre SA, subsidiaries of Ferring Holding SA, Savient will promote Nuflexxa to rheumatologists in the United States.

Pharmabiz (http://www.pharmabiz.com/article/detnews.asp?articleid=26802§ionid=)